Witkiewicz A, Wang J, Schultz E, OConnor T, OConnor T, Levine E
Oncogene. 2025; .
PMID: 40011574
DOI: 10.1038/s41388-025-03308-0.
Witkiewicz A, Schultz E, Wang J, Hamilton D, Levine E, OConnor T
NPJ Precis Oncol. 2023; 7(1):90.
PMID: 37704753
PMC: 10499925.
DOI: 10.1038/s41698-023-00438-0.
Kumarasamy V, Nambiar R, Wang J, Rosenheck H, Witkiewicz A, Knudsen E
Oncogene. 2022; 41(27):3524-3538.
PMID: 35676324
PMC: 10680093.
DOI: 10.1038/s41388-022-02362-2.
Loibl S, Furlanetto J
Breast. 2021; 62 Suppl 1:S70-S79.
PMID: 34930649
PMC: 9097805.
DOI: 10.1016/j.breast.2021.12.008.
Ibrahim A, Bilsland A, Rickelt S, Morris J, Stein T
Breast Cancer Res. 2021; 23(1):90.
PMID: 34565423
PMC: 8474794.
DOI: 10.1186/s13058-021-01470-3.
Pan-cancer application of a lung-adenocarcinoma-derived gene-expression-based prognostic predictor.
Nacer D, Liljedahl H, Karlsson A, Lindgren D, Staaf J
Brief Bioinform. 2021; 22(6).
PMID: 33971670
PMC: 8574611.
DOI: 10.1093/bib/bbab154.
PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance.
Montaudon E, Nikitorowicz-Buniak J, Sourd L, Morisset L, El Botty R, Huguet L
Nat Commun. 2020; 11(1):4053.
PMID: 32792481
PMC: 7426966.
DOI: 10.1038/s41467-020-17697-1.
Liver- and Microbiome-derived Bile Acids Accumulate in Human Breast Tumors and Inhibit Growth and Improve Patient Survival.
Tang W, Putluri V, Ambati C, Dorsey T, Putluri N, Ambs S
Clin Cancer Res. 2019; 25(19):5972-5983.
PMID: 31296531
PMC: 6774910.
DOI: 10.1158/1078-0432.CCR-19-0094.
Molecular Subtypes and Local-Regional Control of Breast Cancer.
Fragomeni S, Sciallis A, Jeruss J
Surg Oncol Clin N Am. 2017; 27(1):95-120.
PMID: 29132568
PMC: 5715810.
DOI: 10.1016/j.soc.2017.08.005.
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.
Knudsen E, Witkiewicz A
Trends Cancer. 2017; 3(1):39-55.
PMID: 28303264
PMC: 5347397.
DOI: 10.1016/j.trecan.2016.11.006.
Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer.
Knudsen E, Witkiewicz A
Oncotarget. 2016; 7(43):69111-69123.
PMID: 27564114
PMC: 5342463.
DOI: 10.18632/oncotarget.11588.
Phospho-TCTP as a therapeutic target of Dihydroartemisinin for aggressive breast cancer cells.
Lucibello M, Adanti S, Antelmi E, Dezi D, Ciafre S, Carcangiu M
Oncotarget. 2015; 6(7):5275-91.
PMID: 25779659
PMC: 4467148.
DOI: 10.18632/oncotarget.2971.
APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation.
Cescon D, Haibe-Kains B, Mak T
Proc Natl Acad Sci U S A. 2015; 112(9):2841-6.
PMID: 25730878
PMC: 4352793.
DOI: 10.1073/pnas.1424869112.
The history and future of targeting cyclin-dependent kinases in cancer therapy.
Asghar U, Witkiewicz A, Turner N, Knudsen E
Nat Rev Drug Discov. 2015; 14(2):130-46.
PMID: 25633797
PMC: 4480421.
DOI: 10.1038/nrd4504.
Systematically defining single-gene determinants of response to neoadjuvant chemotherapy reveals specific biomarkers.
Witkiewicz A, Balaji U, Knudsen E
Clin Cancer Res. 2014; 20(18):4837-48.
PMID: 25047707
PMC: 5286972.
DOI: 10.1158/1078-0432.CCR-14-0885.
Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancer.
Jonsdottir K, Assmus J, Slewa A, Gudlaugsson E, Skaland I, Baak J
PLoS One. 2014; 9(3):e90642.
PMID: 24599057
PMC: 3944091.
DOI: 10.1371/journal.pone.0090642.
Breast tumors with elevated expression of 1q candidate genes confer poor clinical outcome and sensitivity to Ras/PI3K inhibition.
Muthuswami M, Ramesh V, Banerjee S, Thangaraj S, Periasamy J, Bhaskar Rao D
PLoS One. 2013; 8(10):e77553.
PMID: 24147022
PMC: 3798322.
DOI: 10.1371/journal.pone.0077553.
Using Frequent Co-expression Network to Identify Gene Clusters for Breast Cancer Prognosis.
Zhang J, Huang K, Xiang Y, Jin R
Proc Int Joint Conf Bioinforma Syst Biol Intell Comput. 2013; :428-434.
PMID: 23615925
PMC: 3632312.
DOI: 10.1109/IJCBS.2009.29.
Challenges in Biomarker Discovery: Combining Expert Insights with Statistical Analysis of Complex Omics Data.
McDermott J, Wang J, Mitchell H, Webb-Robertson B, Hafen R, Ramey J
Expert Opin Med Diagn. 2013; 7(1):37-51.
PMID: 23335946
PMC: 3548234.
DOI: 10.1517/17530059.2012.718329.
Stromal genes add prognostic information to proliferation and histoclinical markers: a basis for the next generation of breast cancer gene signatures.
Mefford D, Mefford J
PLoS One. 2012; 7(6):e37646.
PMID: 22719844
PMC: 3377707.
DOI: 10.1371/journal.pone.0037646.